Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986521 M4 Receptor Occupancy PET Study in Healthy Adults
NCT07655518Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986521 in schizophrenia (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage occupancy of M4 receptor in the brain. Started Jun 2026; status: recruiting.
02
Drugs
BMS-986521
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07655518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07655518.